OBJECTIVE: To compare the sensitivity to change of two HIV-health-related quality of life (HRQoL) questionnaires--the Medical Outcomes Study (MOS-HIV) and Multidimensional Quality of Life (MQOL-HIV) for use in clinical research. METHODS: A sample of 296 HIV-infected patients starting or switching antiretroviral treatment were randomly assigned either the MOS-HIV or MQOL-HIV questionnaires at baseline and after 3 months of treatment. Ceiling and floor effects were evaluated. Sensitivity to change was assessed by comparing the percentage of dimensions with statistically significant pre-post-treatment changes and the effect sizes in those groups of patients who reported improvement and no change in self-report questions (overall, physical, mental and social health status) and clinical characteristics (number of opportunistic infections, number of symptoms, viral load level and CD4+ count). RESULTS: Ceiling effects were found in HRQoL scores at baseline and after 3 months of treatment in Pain (42.3-41.6%), Role Function (73.1-77.6%) and Social Function (60.9-63%) on MOS-HIV subscales, and in Social Support (38.2-37.6%) and Partner Intimacy (38.2-33.7%) on MQOL-HIV. For patients who improved in self-reported and objective clinical indicators of health status, mean percentage of dimensions with statistically significant pre-post-treatment changes was 86.4% on MOS-HIV and 50% on MQOL-HIV, where mean standardized effect size was 0.45 on MOS-HIV and 0.33 on MQOL-HIV for the total of dimensions. CONCLUSIONS: Based on sensitivity to change the results suggest that for 3 months both questionnaires can be used, but the MOS-HIV is more sensitive than the MQOL-HIV for use in clinical research.
RCT Entities:
OBJECTIVE: To compare the sensitivity to change of two HIV-health-related quality of life (HRQoL) questionnaires--the Medical Outcomes Study (MOS-HIV) and Multidimensional Quality of Life (MQOL-HIV) for use in clinical research. METHODS: A sample of 296 HIV-infectedpatients starting or switching antiretroviral treatment were randomly assigned either the MOS-HIV or MQOL-HIV questionnaires at baseline and after 3 months of treatment. Ceiling and floor effects were evaluated. Sensitivity to change was assessed by comparing the percentage of dimensions with statistically significant pre-post-treatment changes and the effect sizes in those groups of patients who reported improvement and no change in self-report questions (overall, physical, mental and social health status) and clinical characteristics (number of opportunistic infections, number of symptoms, viral load level and CD4+ count). RESULTS: Ceiling effects were found in HRQoL scores at baseline and after 3 months of treatment in Pain (42.3-41.6%), Role Function (73.1-77.6%) and Social Function (60.9-63%) on MOS-HIV subscales, and in Social Support (38.2-37.6%) and Partner Intimacy (38.2-33.7%) on MQOL-HIV. For patients who improved in self-reported and objective clinical indicators of health status, mean percentage of dimensions with statistically significant pre-post-treatment changes was 86.4% on MOS-HIV and 50% on MQOL-HIV, where mean standardized effect size was 0.45 on MOS-HIV and 0.33 on MQOL-HIV for the total of dimensions. CONCLUSIONS: Based on sensitivity to change the results suggest that for 3 months both questionnaires can be used, but the MOS-HIV is more sensitive than the MQOL-HIV for use in clinical research.
Authors: Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: M Bradley Drummond; Gregory D Kirk; Meredith C McCormack; Mariah M Marshall; Erin P Ricketts; Shruti H Mehta; Robert A Wise; Christian A Merlo Journal: Qual Life Res Date: 2010-07-09 Impact factor: 4.147
Authors: G Kemmler; B Schmied; A Shetty-Lee; R Zangerle; H Hinterhuber; G Schüssler; B Mumelter Journal: Qual Life Res Date: 2003-12 Impact factor: 4.147
Authors: E Carballo; C Cadarso-Suárez; I Carrera; J Fraga; J de la Fuente; A Ocampo; R Ojea; A Prieto Journal: Qual Life Res Date: 2004-04 Impact factor: 4.147
Authors: Allison A Lambert; M Bradley Drummond; Annamarie Kisalu; John Moxley; Jeanne Keruly; Richard D Moore; Robert A Wise; Gregory D Kirk Journal: COPD Date: 2016-04-20 Impact factor: 2.409
Authors: Katie E Mosack; Lance S Weinhardt; Jeffrey A Kelly; Cheryl Gore-Felton; Timothy L McAuliffe; Mallory O Johnson; Robert H Remien; Mary Jane Rotheram-Borus; Anke A Ehrhardt; Margaret A Chesney; Stephen F Morin Journal: Behav Med Date: 2009 Impact factor: 3.104